High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

by Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E. Amengual, Donald S. Colbourn, Emily A. Lichtenstein, Karen A. Khan, Lawrence H. Schwartz, Owen A. O’Connor
Published 2016-11-01